You have 0 free articles left this month.
Powered by MOMENTUM MEDIA
lawyers weekly logo
Advertisement
Big Law

Diabetes crisis instigates advice on APAC ‘friendly’ takeover

Thomson Geer has advised China’s Yifan Pharmaceutical Co on its friendly takeover of the Singapore-based biopharmaceutical company SciGen, which is listed on the Australian Securities Exchange.

September 18, 2018 By Grace Ormsby
Share this article on:
insulin, diabetes, crisis
expand image

Firm: Thomson Geer (SciGen and Yifan)

Deal: Thomson Geer advised both parties on the Australian elements of the friendly takeover of SciGen by Yifan.

 
 

Value: $28 million

Area: M&A, Corporate

Key players: Thomson Geer’s team was led by partner Tim Flahvin and senior associate Venks Ananthakrishnan.

Deal significance: Established in 1988, SciGen focuses on endocrinology, gastroenterology and immunology. It is also a human insulin producer.

Yifan is seeking to enhance its research and production capacity of insulin products. Its purchase of SciGen gives it access to a portfolio of products, inclusive of insulin. The takeover will also provide it access to a well-established sales network that covers more than 20 countries and regions, especially within the APAC region.

According to the Journal of the American Medical Association, diabetes is emerging as a national health crisis for China. It has reported that half of the country’s population has diabetes or is pre-diabetic.

The Yifan takeover of SciGen was effected with co-operation from SciGen’s controlling shareholder, Warsaw Stock Exchange-listed company Bioton.

You need to be a member to post comments. Become a member today